Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes
JAMA Network Open · 25.08.2023 · 6 (8) · e2330885
DOI: 10.1001/jamanetworkopen.2023.30885 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 25.08.2023. Verfasst von Jie Wei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Health Management Center, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Gout, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Importance Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a lower risk of incident gout; however, their association with recurrent flares is unknown.
Objective
To examine the association of SGLT2i vs active comparators (ie, glucagonlike peptide-1 receptor agonists [GLP-1 RA] or dipeptidyl peptidase-4 inhibitors [DPP-4i]) with the risk of recurrent gout flares and all-cause mortality among patients with gout and type 2 diabetes. Design, Setting, and Participants This population-based retrospective cohort study was performed from January 1, 2013, to March 31, 2022, using a UK primary care database. Participants included patients with gout and type 2 diabetes with visits to their general practitioners. Exposures Initiation of treatment with SGLT2i or active comparators. Main Outcomes and Measures The primary outcome was the number of recurrent gout flares ascertained using recorded codes and prescription records. Secondary outcomes were the first recurrent gout flare and all-cause mortality. The association of SGLT2i compared with active comparators for the risk of recurrent flares, the first recurrent flare, and all-cause mortality was assessed using Poisson regression or the Cox proportional hazards model with propensity score overlap weighting.
Results
Of a total of 5931 patients included in the analysis (mean [SD] age, 66.0 [11.6] years; 4604 [77.6%] men), 1548 initiated SGLT2i treatment and 4383 initiated treatment with active comparators during the study period. The relative rate of the recurrent flares with SGLT2i vs active comparators was 0.79 (95% CI, 0.65-0.97). Similar results were observed in the association of SGLT2i with the rate of recurrent flares when compared with DPP-4i or GLP-1 RA. For the first recurrent flare for SGLT2i vs active comparators, rate difference was −8.8 (95% CI, −17.2 to −0.4) per 1000 person-years and the hazard ratio was 0.81 (95% CI, 0.65-0.98). All-cause mortality per 1000 person-years was 18.8 for SGLT2i and 24.9 for active comparators, with rate difference of −6.1 (95% CI, −10.6 to −1.6) per 1000 person-years and hazard ratio of 0.71 (95% CI, 0.52-0.97). Conclusions and Relevance The findings of this cohort study suggest that SGLT2i were associated with a lower risk of recurrent gout flares and mortality than their active comparators in patients with gout and type 2 diabetes. These findings further suggest that SGLT2i could help reduce the burden of recurrent gout flares and could also narrow the mortality gap between patients with gout and the general population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Health Management Center, Xiangya Hospital, Central South University, Changsha, China.
- Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
- Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China.
- Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China.
- Key Laboratory of Aging-Related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China.
- Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Zitieren
APA
Wei, J., Choi, H. K., Dalbeth, N., Li, X., Li, C., Zeng, C., Lei, G., & Zhang, Y. (2023). Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes. JAMA Network Open, 6(8), e2330885. https://doi.org/10.1001/jamanetworkopen.2023.30885
Vancouver
Wei J, Choi HK, Dalbeth N, Li X, Li C, Zeng C, et al. Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes. JAMA Network Open. 2023;6(8):e2330885. doi:10.1001/jamanetworkopen.2023.30885
BibTeX
@article{Wei2023,
author = {Wei, Jie and Choi, Hyon K and Dalbeth, Nicola and Li, Xiaoxiao and Li, Changjun and Zeng, Chao and Lei, Guanghua and Zhang, Yuqing},
title = {Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {8},
pages = {e2330885},
doi = {10.1001/jamanetworkopen.2023.30885}
}
EUVIMED